HOME >> BIOLOGY >> NEWS
New therapies expected from better understanding of RNA, says UH prof

HOUSTON, Oct. 4, 2005 One professor's research in RNA with immediate application in monitoring bacteria in the environment and potentially allowing for advances in biotechnology will be discussed at the annual University of Houston Sigma Xi lecture at 4 p.m., Monday, Oct. 10. The event is open to the public.

As the 2005 recipient of the Sigma Xi Faculty Research Award, George E. Fox, UH professor of biology and biochemistry and professor of chemical engineering, will present a lecture on his explorations in a local region of RNA sequence space. He will describe studies that provide a better understanding of what is possible and what is not when modifying a naturally occurring RNA. This work furthers efforts to develop general design principles for RNA that can be used in emerging biotechnology applications. This is especially significant now because RNA has recently been discovered to be unexpectedly involved in the regulation of gene expression in mammalian cells. Hence, the ability to design novel RNAs is expected to facilitate research leading to new therapies for a variety of human ailments.

The Scientific Research Society of Sigma Xi is the global honor society of scientists and engineers that promotes scientific achievement with chapters in every college and university in the United States. Some 180 Sigma Xi members are Nobel laureates and many more have been elected to the National Academies of Science and Engineering. The UH chapter of Sigma Xi is honoring Fox with the award "for distinguished contributions to scientific knowledge and its applications." The honor also includes a cash prize of $2,000.

Since coming to UH in 1977, Fox has held numerous positions including vice chair of the Department of Biology and Biochemistry from 1998 to 2000 and director of the Institute for Molecular Biology from 1988 to 2001. He is the author or co-author of more than 110 peer review publications and has received numerous honors and
'"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
4-Oct-2005


Page: 1 2

Related biology news :

1. New asthma gene could lead to new therapies
2. Scientists decode RNA mystery, will help aim drug therapies
3. Genomic signatures identify targeted therapies for lung cancer
4. Existence of muscle-building stem cells points to regenerative therapies for muscular disease
5. Antibody-based therapies effective at controlling malaria
6. Preterm infants with RDS -- surfactant replacement therapies improves neonatal survival
7. UBC discovery may lead to smart therapies for breast, ovarian cancer
8. NDDO and ESMO joined by US National Cancer Institute in conferences on targeted cancer therapies
9. U of MN adult stem cell research shows promise for transplant therapies
10. Boost for new cancer therapies
11. Studies at cancer conference show new therapies changing outlook for blood cancer patients

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New therapies expected from better understanding RNA says prof

(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
(Date:5/21/2013)... Michigan Water Center today awarded 12 research grants, ... and protection efforts. , The two-year grants of ... efforts to track the remediation of harmful algae ... non-native weedy plant invasions; study chromosomal damage in ... restoration activities. , The grants were awarded to ...
(Date:5/21/2013)... an uphill battle? Try staying fit in space, where ... and bone. , That,s the challenge a group of ... three-year, $1.2 million grant from NASA. Their goal is ... missions. , "You could give astronauts the best exercise ... to stick to it, it isn,t going to help," ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Fueling fitness on the final frontier 2
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) , ... pleased to announce a sponsorship agreement with Erebus Motorsport ... distributor of DrugCheck® onsite testing devices, manufactured by EDI. ... Austin 400 May 17-19 in Austin, Texas. , Royal ... each car of the Erebus Motorsport team displaying the ...
(Date:5/22/2013)... Chester, PA (PRWEB) May 22, 2013 ... company as Fermentation Manager. Mr. McErlean has an ... variety of leadership positions throughout his career. ... “We are very pleased to have Mike join our ... newly installed large scale fermentation and downstream ...
(Date:5/22/2013)... 22, 2013 The ability to ... the information they encode. There are now a ... sequencing of ribosome protected fragments) that dramatically expand ... Keynote speakers include Dr. Jonathan Weissman, an Investigator ... Howard Hughes Medical Institute, who will present recent ...
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
Breaking Biology Technology:Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Envera Appoints Michael McErlean Fermentation Manager 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
Cached News: